Oramed Pharmaceuticals (NASDAQ:ORMP) Stock Rating Upgraded by StockNews.com

Oramed Pharmaceuticals (NASDAQ:ORMP) was upgraded by equities research analysts at StockNews.com from a “sell” rating to a “hold” rating in a note issued to investors on Friday.

Separately, HC Wainwright reissued a “neutral” rating on shares of Oramed Pharmaceuticals in a report on Monday, September 9th.

Oramed Pharmaceuticals Stock Performance

Shares of ORMP opened at $2.36 on Friday. The firm’s 50-day simple moving average is $2.37 and its 200 day simple moving average is $2.40. The firm has a market cap of $95.14 million, a P/E ratio of 21.45 and a beta of 1.70. Oramed Pharmaceuticals has a 52 week low of $2.00 and a 52 week high of $3.67.

Hedge Funds Weigh In On Oramed Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the stock. XTX Topco Ltd lifted its position in shares of Oramed Pharmaceuticals by 59.7% during the 3rd quarter. XTX Topco Ltd now owns 24,716 shares of the biotechnology company’s stock valued at $60,000 after acquiring an additional 9,242 shares during the period. Murchinson Ltd. raised its stake in Oramed Pharmaceuticals by 0.5% in the third quarter. Murchinson Ltd. now owns 1,708,879 shares of the biotechnology company’s stock valued at $4,170,000 after purchasing an additional 8,889 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. bought a new stake in Oramed Pharmaceuticals during the third quarter worth about $272,000. BML Capital Management LLC grew its stake in Oramed Pharmaceuticals by 62.1% during the third quarter. BML Capital Management LLC now owns 2,186,191 shares of the biotechnology company’s stock worth $5,334,000 after buying an additional 837,153 shares in the last quarter. Finally, Renaissance Technologies LLC grew its stake in Oramed Pharmaceuticals by 89.0% during the second quarter. Renaissance Technologies LLC now owns 230,800 shares of the biotechnology company’s stock worth $593,000 after buying an additional 108,700 shares in the last quarter. Institutional investors own 12.73% of the company’s stock.

Oramed Pharmaceuticals Company Profile

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.